10-Q: AIXIN LIFE INTERNATIONAL Reports Steep Revenue Decline and Widening Losses Amid Economic Headwinds, Raises Going Concern Doubts

AIXIN LIFE INTERNATIONAL, INC. (AIXN) reported a significant 53% drop in total revenue and a 20% increase in net loss for the first quarter of 2025, raising substantial doubt about its ability to continue as a going concern.

Summary

• Total revenue for the three months ended March 31, 2025, decreased by 53% to $398,831 from $851,559 in the same period of 2024.
• The company experienced a net loss of $721,708 for Q1 2025, a 20% increase from the $603,600 net loss in Q1 2024.
• Loss from operations increased by 10% to $682,485 in Q1 2025 from $621,246 in Q1 2024.
• Net cash used in operating activities worsened to $675,948 in Q1 2025, compared to $461,451 in Q1 2024.
• As of March 31, 2025, the company had a working capital deficit of $6,708,468.
• Cash and cash equivalents remained low at $63,109 as of March 31, 2025, a slight increase from $62,310 at December 31, 2024, primarily due to financing activities.
• The company's direct sales revenue plummeted by 88% to $20,631, and pharmacy revenue decreased by 85% to $35,966.
• Hotel revenue declined by 48% to $80,706, and manufacture and sales revenue saw a 10% decrease to $261,528.
• The increase in net loss was mainly attributed to decreased sales and reduced other income, partially offset by lower operating costs and expenses.
• The company's disclosure controls and procedures were deemed not effective as of March 31, 2025, due to limited resources and deficiencies in internal control over financial reporting.

Sentiment

Score: 1

Explanation: The company's financial performance is severely negative, with substantial revenue declines, widening losses, increased cash burn, and a significant working capital deficit. The explicit 'going concern' warning and ineffective internal controls indicate critical operational and financial distress, warranting the lowest possible sentiment score.

Positives

• Total operating costs and expenses decreased by 27% to $1,081,316 in Q1 2025 from $1,472,805 in Q1 2024, primarily due to decreased stock-based compensation, depreciation, and travel expenses.
• The hotel segment's loss from operations decreased by $127,609, and direct sales segment's loss decreased by $52,310.
• Net cash provided by financing activities increased to $676,398 in Q1 2025 from $383,802 in Q1 2024, largely due to advances from related parties.

Negatives

• Total revenue decreased by 53% year-over-year, indicating a significant downturn across all business segments.
• Net loss increased by 20% to $721,708, further eroding shareholder equity.
• The company reported a substantial working capital deficit of $6,708,468 as of March 31, 2025.
• Net cash used in operating activities increased significantly, demonstrating a higher cash burn from core operations.
• The pharmacy segment's loss from operations increased by approximately $122,298, and the manufacture and sales segment's loss increased by $118,860.
• Cost of sales as a percentage of direct sales increased to 28% in Q1 2025 from 12% in Q1 2024, indicating lower profit margins on direct sales.
• Cost of sales as a percentage of pharmacy sales increased to 67% in Q1 2025 from 33% in Q1 2024, due to decreased sales and promotional activities like price discounts.
• Cost of sales for the manufacture and sale segment increased to 108% of sales, indicating that costs exceeded revenue for this segment, primarily due to fixed costs and decreased activity during the Chinese New Year holiday.
• The company has a high concentration risk with one customer accounting for 45% of total revenue in Q1 2025.
• Management concluded that disclosure controls and procedures were not effective as of March 31, 2025, citing limited resources and deficiencies in internal control over financial reporting.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring net losses, negative cash flows from operations, and a significant working capital deficit.
• Dependence on the successful implementation of a liquidity plan, including continuous cost reductions, sales of higher margin products, and raising cash through related party loans and potential equity offerings, with no assurance of success.
• Exposure to the political, economic, and legal environments in the PRC, which can adversely affect business, financial condition, and results of operations.
• Risks associated with foreign currency exchange rates, as sales, purchases, expenses, assets, and liabilities are denominated in RMB, which is not freely convertible.
• High customer concentration risk, with one customer accounting for 45% of total revenue in Q1 2025, making the company vulnerable to the loss of this customer.
• Supplier concentration risk, with three major suppliers accounting for over 10% of total purchases in Q1 2025.
• Inability to achieve profitability and generate positive cash flow due to challenges in attracting and retaining a large and loyal customer base and cost-effectively providing products.
• Unproven profitability of the new and evolving revenue model, with potential for continued operating losses.
• Adverse impact of inflation on results of operations, particularly rising prices for products and operating costs, if increases cannot be passed on to customers.
• Risks inherent in the development of a new business enterprise within extremely competitive industries.
• Potential for dilution to current shareholders from additional issuances of equity or convertible debt securities.
• Unavailability of additional financing on acceptable terms, which could restrict business operations.
• Impact of global events (pandemics, wars, shifts in international alliances, tariffs) on capital markets and the company's ability to raise funds.
• Ineffective disclosure controls and procedures and material weaknesses in internal control over financial reporting, which could adversely affect the company's ability to record, process, summarize, and report financial information accurately.

Future Outlook

The company aims to achieve positive cash-inflow from operating activities through continuous cost reductions and the sales of higher margin products. It also plans to raise cash through loans from related parties and potential equity offerings. The company intends to look for additional opportunities to profit from the growing healthcare market in China, including expanding product lines through internal research and acquisitions, acquiring additional pharmacies and retail outlets, and potentially operating nursing homes and clinics. However, there is no assurance that the liquidity plan will be successfully implemented or that the business objectives will be achieved.

Management Comments

• "Management believes that it has developed a liquidity plan... that, if executed successfully, should provide sufficient liquidity to meet the Company’s obligations as they become due for a reasonable period of time, and allow the development of its core business."
• "While our management believes that the measures in our liquidity plan including those described above will be adequate to satisfy our liquidity requirements for the twelve months after the date of the financial statements contained in this Report are issued, there is no assurance that the liquidity plan will be successfully implemented."
• "The decrease in direct sales revenue was mainly due to the economic downturn as marketing and promotional activities became more challenging compared to last year."
• "The decrease in [pharmacy] revenue was mainly due to the economic downturn as marketing and promotional activities did not generate anticipated revenues, as well as the convenience of online shopping leading to decreased sales in physical stores."
• "Our hotel revenue decreased... due to the economic downturn and the slowdown in the catering industry."
• "The decrease in manufacture and sales revenue was mainly due to the economic downturn as marketing and promotional activities become more challenging compared to last year."
• "The primary reason for the increase in cost of sales [for manufacture and sale segment] was that fixed and constant costs such as rents and depreciation expense remained same while our manufacture activities decreased due to the Chinese New Year holiday, which led to increased unit cost."
• "Management of AiXin Life International, Inc. is responsible for maintaining disclosure controls and procedures... they concluded that at March 31, 2025, such disclosure controls and procedures were not effective. This was due to our limited resources, including the absence of a financial staff with accounting and financial expertise and deficiencies in the design or operation of our internal control over financial reporting that adversely affected our disclosure controls and that may be considered to be material weaknesses."

Industry Context

The company operates in the health and wellness market in China, which is described as growing, but faces challenges from an economic downturn impacting marketing and promotional activities, and a shift towards online shopping affecting physical pharmacy sales. The catering industry slowdown also negatively impacted hotel revenue. The company aims to differentiate itself through product design, manufacturing, and an omni-channel distribution network, but its ability to compete effectively and achieve profitability is unproven.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess against global benchmarks. However, the significant revenue decline (53%) across all segments and the worsening net loss (20% increase) are substantially worse than typical growth or stability expected in a 'growing' healthcare market, suggesting underperformance relative to general industry trends.
• The increase in cost of sales as a percentage of revenue for direct sales (from 12% to 28%) and pharmacies (from 33% to 67%), and especially for manufacture and sale (from 79% to 108%), indicates severe margin compression or operational inefficiencies that are likely below industry standards for healthy businesses.
• The explicit 'going concern' warning and the admission of 'not effective' disclosure controls and 'material weaknesses' in internal control over financial reporting are critical red flags, far below the governance and financial health standards expected of publicly traded companies, regardless of industry.

Corporate Governance

Legal Proceedings

• There is no pending litigation to which the company is presently a party or to which its property is subject which is likely to have a material impact on its financial condition.

Related Party Transactions

• Accounts receivable related parties totaled $394,974 as of March 31, 2025, primarily from entities controlled by Mr. Quanzhong Lin (Chairman, CEO, major shareholder) and Huiliang Jiao (Director).
• Accounts payable related parties totaled $88,996 as of March 31, 2025, primarily to entities controlled by Mr. Quanzhong Lin and Huiliang Jiao.
• Due from related parties totaled $4,127 as of March 31, 2025, for working capital purposes, payable on demand, and bearing no interest.
• Due to related parties totaled $3,818,111 as of March 31, 2025, primarily from Mr. Quanzhong Lin ($3,695,079) and Huiliang Jiao ($117,446), for working capital purposes, payable on demand, and bearing no interest.
• The company received $1,421,841 in advances from related parties during Q1 2025, and made repayments of $530,559 to related parties.
• Runcangsheng leases its office from Xiaoyan Zhou, wife of Director Huiliang Jiao, with a renewed lease term until December 31, 2025, at a monthly rent of RMB 5,000 ($690).

Stakeholder Impact

• **Shareholders:** Significant negative impact due to widening net losses, substantial revenue decline, and a 'going concern' warning, leading to potential further dilution from future equity offerings and a likely decrease in share price.
• **Employees:** Potential impact from cost reduction initiatives and the company's overall financial distress, though no specific layoffs or changes were mentioned.
• **Customers:** Potential impact on product availability or service quality if financial difficulties persist, though the company aims to continue providing health and wellness products.
• **Suppliers:** Risk of delayed payments or reduced orders due to the company's working capital deficit and declining sales, especially for the three major suppliers.
• **Creditors (including related parties):** Increased risk of repayment given the 'going concern' doubt and reliance on related party financing, although related party loans are currently providing liquidity.

Next Steps

• Implement liquidity plan measures, including continuous cost reductions and sales of higher margin products.
• Pursue financing arrangements, specifically raising cash through loans from related parties and potential equity offerings.
• Explore expanding product lines through internal research and acquiring complementary products from third parties.
• Acquire additional pharmacies and other retail outlets.
• Potentially operate nursing homes and clinics which provide medical care to clients.
• Remediate identified material weaknesses in disclosure controls and internal control over financial reporting by designating individuals responsible for identifying reportable developments and implementing improved procedures.

Key Dates

Recommendation

Keywords

Health and Wellness, Nutritional Products, Pharmacies, Hotel Management, Direct Sales, Manufacturing, China Market, SEC Filing, 10-Q, Financial Performance, Going Concern, Working Capital Deficit, Revenue Decline, Net Loss, Cash Flow, Related Party Transactions, Internal Controls, Risk Factors, OTC Markets